In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
The results of the EMBRACA trial were presented today at the 2017 San Antonio Breast Cancer...
Study results revealed previously unknown interplay between two key enzymes and a novel understanding of how brain cancer tumors form and...
The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (...
Researchers at The University of Texas MD Anderson Cancer Center will
present their latest findings involving drug treatments for blood
cancers at the American Society of Hematology’s (ASH) Annual Meeting
& Exposition Dec. 8-12 in Atlanta.
“There can be no
doubt that we are in an exciting new era of treatment of blood cancers
as evidenced by key presentations by MD Anderson researchers at this
year’s ASH meeting,” said Patrick...
The University of Texas MD Anderson Cancer Center today welcomes Peter WT Pisters, M.D., as its fifth full-time president in the institution...
As an institution dedicated to ending cancer, The University of Texas MD Anderson Cancer Center is committed to promoting cancer prevention...
In recognition of their contributions to basic, translational, and clinical research, six faculty members from The University of Texas...
Research from The University of Texas MD Anderson Cancer Center finds adherence to surgical treatment guidelines has improved significantly...
Seres Therapeutics, Inc., The University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy today...
Thousands of patients, family members, volunteers, friends and employees of The University of Texas MD Anderson Cancer Center participated...